Article
Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
International journal of clinical practice. Supplement - 1 May 2015
Liu L-S, Li J, Chen X-T, Zhang H-X, Fu Q, Wang H-Y, Xiong Y-Y, Liu S, Liu X-M, Li J-L, Huang M, Wang C-X
Abstract excerpt
AIMS: To assess the efficacy and safety of tacrolimus and cyclosporin A (CsA)-based immunosuppressive regimens in Chinese de novo kidney transplant recipients who are CYP3A5 expressers. METHODS: The CYP3A5 (6986 A>G, rs776746) polymorphism of eligible patients was determined before transplantation. De novo kidney transplant recipients enrolled in this study were assigned to tacrolimus (Tac group) or CsA (CsA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.